Daily Endocrinology Research Analysis
Analyzed 80 papers and selected 3 impactful papers.
Summary
Three impactful endocrinology papers span therapeutics, mechanistic biology, and environmental health: a randomized phase 1b/2a trial of a new GLP-1 receptor agonist (GZR18) achieved up to 17.8% weight loss with acceptable safety; integrative human-genetic and animal data implicate Wnt/β-catenin (CTNNB1) and DLK1 in type 2 diabetes pathophysiology; and microplastics, particularly PVC, were identified in human thyroid tissue with higher burden in autoimmune thyroiditis.
Research Themes
- Next-generation incretin therapies for obesity
- Wnt/β-catenin signaling and islet biology in type 2 diabetes
- Environmental microplastics and thyroid autoimmunity
Selected Articles
1. GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial.
In a randomized, placebo-controlled phase 1b/2a trial (n=60), GZR18 induced substantial weight loss: −9.36% vs placebo in Part A and −17.8% (QW) and −12.8% (Q2W) vs placebo in Part B over up to 35 weeks, with mainly mild-to-moderate gastrointestinal adverse events and no drug-related serious events. These data support further development of once-weekly/bi-weekly dosing for obesity management.
Impact: Early randomized evidence shows double-digit weight loss with a new GLP-1 analog using flexible dosing, suggesting potential class expansion and dosing convenience for obesity care.
Clinical Implications: If confirmed in larger phase 3 trials, GZR18 could expand GLP-1RA options with effective once-weekly or bi-weekly dosing, requiring standard GI AE monitoring and dose titration strategies used across the class.
Key Findings
- Randomized, placebo-controlled trial (n=60) in Chinese adults with overweight/obesity.
- Body weight decreased by −9.36% (Part A) and by −17.8% (QW) and −12.8% (Q2W) vs placebo over up to 35 weeks.
- Safety profile showed mostly mild-to-moderate gastrointestinal AEs with no investigational-product-related serious adverse events.
Methodological Strengths
- Randomized, placebo-controlled design across two dosing schedules (QW and Q2W).
- Prospective assessment over 26–35 weeks with predefined endpoints.
Limitations
- Small early-phase sample size (n=60) with 46 completers and short-to-moderate duration.
- Single-country population; generalizability and long-term safety/efficacy remain to be established.
Future Directions: Conduct larger, multi-regional phase 3 trials assessing long-term cardiometabolic outcomes, durability of weight loss, optimal titration, and comparative effectiveness versus established GLP-1/GIP agents.
GZR18 is a glucagon-like peptide-1 receptor agonist under development for overweight/obesity. In this randomized, placebo-controlled phase 1b/2a trial in Chinese adults with overweight or obesity, different dose titration regimens and dosing frequencies (once-weekly [QW] vs. bi-weekly [Q2W]) are evaluated to assess safety and weight-loss efficacy over 26 weeks (Part A) or 35 weeks (Part B). Sixty participants are enrolled, of whom 46 complete the trial. The least-squares mean change in body wei
2. CTNNB1 Genetic Variation and Its Interaction With DLK1 in Type 2 Diabetes Mellitus.
Integrating bioinformatics, human genetics (n=988), and mouse models, the study identifies CTNNB1 (β-catenin) downregulation in T2D, a protective association of CTNNB1 rs1798802 GG genotype (OR 0.640), and reduced β-catenin and DLK1 in diabetic islets with subcellular colocalization. Findings implicate Wnt/β-catenin signaling and a potential CTNNB1–DLK1 interaction in islet dysfunction.
Impact: This translational study links human genetic variation and islet biology via Wnt/β-catenin, nominating β-catenin (CTNNB1) as a potential therapeutic target in type 2 diabetes.
Clinical Implications: While not immediately practice-changing, the work supports targeting Wnt/β-catenin–DLK1 axes to preserve β-cell function and encourages genotype-informed risk stratification research.
Key Findings
- CTNNB1 shows differential expression in T2D datasets; network and docking suggest interaction with DLK1.
- In humans (n=988), CTNNB1 rs1798802 GG genotype is associated with lower T2D risk (OR 0.640; p=0.015) and serum β-catenin is reduced in T2D.
- In HFD-induced diabetic mice, β-catenin and DLK1 levels are decreased in pancreatic tissue with immunofluorescent colocalization in islets.
Methodological Strengths
- Multimodal approach combining transcriptomics, human genetic association, protein quantification, and in vivo validation.
- Large human sample (n=988) with convergent animal model evidence.
Limitations
- Case–control design limits causal inference; external replication not reported.
- Molecular docking and colocalization suggest but do not prove direct CTNNB1–DLK1 binding/function.
Future Directions: Perform mechanistic studies (e.g., perturbation of CTNNB1–DLK1 in human islets), longitudinal cohorts for predictive value, and early-phase trials of Wnt/β-catenin modulators for β-cell preservation.
To investigate the association between Catenin Beta 1 (CTNNB1) gene polymorphisms and type 2 diabetes mellitus (T2DM), as well as the interacting molecules of CTNNB1. Bioinformatic analysis of publicly available transcriptomic datasets derived from T2DM samples identified a panel of differentially expressed genes (DEGs), among which CTNNB1 exhibited significant differential expression. Subsequent functional enrichment analysis and molecular docking revealed a co-expression network between CTNNB1 an
3. Preliminary Evidence of Microplastics in the Human Thyroid and Their Potential Association with Autoimmune Thyroiditis.
Using Py-GC/MS and micro-Raman spectroscopy in a case-control analysis (n=58), microplastics were detected in human thyroid tissue, with significantly higher total MP burden and particle abundance in AIT versus controls; PVC enrichment predominated. Morphology did not differ between groups. Findings suggest an environmental contribution to thyroid autoimmunity warranting mechanistic and epidemiologic follow-up.
Impact: This is among the first demonstrations of microplastics in human thyroid tissue and their association with autoimmune thyroiditis, bridging environmental exposure with endocrine autoimmunity.
Clinical Implications: While causality is unproven, clinicians should be aware of potential environmental contributors to thyroid autoimmunity; public health measures reducing PVC exposure and research into biomarkers of exposure may become relevant.
Key Findings
- Microplastics were detected in thyroid tissues of both AIT and control groups via Py-GC/MS.
- Total MP concentration was higher in AIT (median 19.9 vs 1.9 μg/g; p=0.012), driven by PVC enrichment.
- Micro-Raman confirmed particle identities (33.9–1467 µm) and higher particle abundance in AIT (172 vs 50.2 items/g; p=0.037), with no morphological differences.
Methodological Strengths
- Orthogonal analytical chemistry (Py-GC/MS and micro-Raman) with particle-level characterization.
- Age- and sex-matched case-control design with quantitative burden metrics.
Limitations
- Single-center, small sample size limits generalizability.
- Cross-sectional design precludes causal inference; potential contamination controls are critical though not detailed here.
Future Directions: Undertake multicenter studies with rigorous contamination controls, longitudinal exposure assessment, mechanistic AOP-based models, and epidemiologic linkage between specific polymers (e.g., PVC) and thyroid autoimmunity.
BACKGROUND: Microplastics (MPs) have been identified in multiple human tissues and are increasingly implicated in systemic health risks. Their presence in the thyroid gland, however, remains unexamined. Autoimmune thyroiditis (AIT) is the most frequent autoimmune thyroid disorder and the leading cause of hypothyroidism. This study aims to detect the presence of MPs in the thyroid and their potential relevance to AIT. METHODS: In this case-control study, thyroid tissues were obtained from 29 patie